Acrux (ASX: ACR) | Investor Webinar: Female Testosterone MDTS and Recent FDA Feedback

Acrux (ASX:ACR) CEO John Warmbrunn recently hosted an investor webinar providing an update on the Company's Female Testosterone MDTS program, including recent feedback from the U.S. Food and Drug Administration (FDA) and the Company's Phase III development pathway. In this webinar, John Warmbrunn discusses: Updates on Female Testosterone MDTS Recent FDA feedback and the Company's Phase III development pathway -Key themes from the FDA's recent public workshop on testosterone use in menopausal women Investor Q&A with management Watch the full webinar to hear directly from Acrux's CEO on the Company's development program and latest regulatory updates.